Telehealth CAC & LTV Benchmarks for 2026 (and Why Ownership Changes the Math)

Telehealth CAC ranges from $70–$90 for hair/skin to $200–$350 for men's TRT or HRT, depending on category and channel mix (estimated from public sources). LTV typically runs 3–8x CAC on refill-based models. Operators who own their patient data and order system of record capture the full LTV; those on third-party platforms leak 15–30% to revenue share.

If you are building a DTC Rx or telehealth brand in 2026, the question is not whether the unit economics work. They do — chronic-condition categories with recurring prescriptions produce excellent LTV when you run them correctly. The question is whether you capture that LTV or whether your platform does.

---

What Does CAC Actually Look Like Across Telehealth Categories?

The honest answer is: it varies more by category than most operators expect. A men's hair program and a TRT program can share the same ad account and still produce CAC figures that are 3x apart. Here are directional ranges compiled from public filings, industry reports, and operator conversations (mark these as estimated from public sources — your numbers will depend on channel, creative, and funnel quality):

Category	Estimated CAC Range	Primary Channel Mix	Notes
Men's TRT / testosterone	$150–$350	Paid social, YouTube, podcast	High-intent but competitive; lab requirement adds friction
Men's ED	$80–$200	Paid search, social	Strong conversion on async consult; short path to purchase
Women's HRT / menopause	$120–$280	Meta, Pinterest, email	Underserved; CPMs rising fast as category heats up
Hair loss (men's & women's)	$60–$130	Paid social, SEO	High volume, lower AOV; topical + oral mix
Tretinoin / skin / acne	$50–$110	TikTok, Instagram, SEO	Youngest demographic; strong organic amplification
LDN (low-dose naltrexone)	$90–$180	Organic, community, podcast	Niche but very high LTV; patient advocacy drives referral
Peptides (BPC-157, etc.)	$130–$300	Podcast, direct, community	Regulatory overhang; higher-education buyer
Oral weight management (non-GLP-1)	$100–$220	Paid social, search	Growing headroom as compounded GLP-1 window closes

What moves you inside these ranges:

• Async vs. synchronous consult. Async intake (questionnaire-only) typically cuts CAC 20–40% versus live video — friction directly maps to drop-off.
• Initial visit fee. Charging $0–$30 for consultation lowers the top-of-funnel bar. Whether that improves blended unit economics depends entirely on your refill conversion.
• Channel concentration. Brands still buying nearly all media on Meta have seen CPMs climb 25–40% year-over-year in health categories. Diversification to search, podcast, and programmatic is no longer optional.
• Provider approval speed. Every hour between patient intake and provider sign-off leaks conversion. Nothing ships without a licensed provider — that is non-negotiable — but the operational question is how fast that happens. Sub-60-second order dispatch after approval is table stakes in 2026.

---

What Is a Realistic LTV for a Telehealth Patient?

LTV in telehealth is almost entirely a function of refill retention. Most chronic-condition protocols run monthly or quarterly, which means a patient who stays 12 months is worth 4–12x their first order depending on AOV and margin.

Rough LTV benchmarks by category (estimated):

Category	Avg. Monthly AOV	12-Month Retention (estimated)	12-Month LTV
TRT	$120–$180/mo	55–65%	$800–$1,400
ED (ongoing)	$60–$100/mo	40–55%	$300–$600
HRT	$80–$150/mo	60–70%	$576–$1,260
Hair (topical + oral)	$40–$80/mo	45–60%	$216–$576
Tretinoin / skin	$35–$65/mo	35–50%	$147–$390
LDN	$60–$120/mo	65–75%	$468–$1,080

These are not guarantees. They reflect what operators report when retention is actively managed — meaning proactive refill reminders, easy async check-ins, and frictionless reorder flows. Poor checkout UX and manual refill processes can cut these by 30–50%.

The LTV:CAC ratios that matter for scaling:

• Below 2:1 — You are losing money or breaking even. Not a scalable acquisition model.
• 3:1 — Acceptable for a funded brand burning toward growth. Not a sustainable operating posture long-term.
• 4–6:1 — The target range for a well-run DTC Rx brand. Enough margin to reinvest in acquisition and still generate cash.
• Above 6:1 — Either you have exceptional retention, a very low-CAC channel, or you are under-investing in growth. All three are possible; only the first two are good.

---

How Platform Revenue Share Erodes Your LTV (The Math Nobody Talks About)

Here is the part most operators only discover after they have already scaled on someone else's platform.

Assume a TRT patient with a 12-month LTV of $1,100 and a CAC of $220. That is a 5:1 ratio — solid.

Now assume your fulfillment platform takes 20% of revenue. On $1,100 over 12 months, that is $220 going to the platform. Your effective LTV drops to $880. Your LTV:CAC is now 4:1.

Still workable. But that 20% compounds:

• You cannot use the patient data to cross-sell — the platform owns the relationship.
• You cannot port the patient to a different pharmacy if your current one raises prices or loses formulary items.
• Refill reminders go out under the platform's brand, not yours. Every retention touchpoint builds their equity, not yours.
• If you ever try to migrate, you may not own the prescription history. Patient acquisition cost is sunk; rebuilding retention from zero is not.

The real LTV:CAC comparison:

Model	12-Month LTV	CAC	Ratio
Platform-dependent (20% rev share)	$880	$220	4:1
Platform-dependent (25% rev share)	$825	$220	3.75:1
Operator-owned stack (you own SOoR)	$1,100	$220	5:1
Operator-owned + cross-sell (e.g., TRT → peptide add-on)	$1,350	$220	6.1:1

The gap between 3.75:1 and 6.1:1 is not a rounding error. At 1,000 patients, that is the difference between a business worth building and one that is effectively a lead-gen operation for your platform vendor.

---

The Refill Is Where the Business Actually Lives

[See our full post on building a subscription and refill engine that retains patients →]

Acquisition gets all the attention. The economics live in refill.

A few principles that hold across categories:

1. The 90-day cliff is real. Most churn happens between days 30–90. A patient who refills twice has materially better long-term retention than one who refills once. Your ops — refill reminders, easy async follow-up, frictionless reorder — need to be tightest in that window.

2. Provider continuity matters. Patients who see the same provider (even asynchronously) churn less. This is operationally non-trivial when you scale, but it is worth tracking as a variable in your retention data.

3. Multi-protocol expands LTV without new CAC. A patient on tretinoin who adds oral minoxidil or a peptide protocol has not cost you a second acquisition dollar. The cross-sell multiplier is enormous when the patient record and the ordering system are yours to query.

4. Nothing ships without a licensed provider — and that is also a retention advantage. Patients who know every refill is clinically reviewed stay longer and trust the brand more. This is not just a compliance posture; it is a retention driver. Make it visible in your communications.

---

What Category Should You Launch Into First?

[See our post on launching a men's health vertical in under 60 days →]

There is no universally correct answer, but here is the operator-level logic:

If you want lowest CAC at launch: Tretinoin/skin or men's hair. Proven demand, low CPMs relative to other health categories, relatively low regulatory complexity for topical protocols.

If you want highest LTV per patient: TRT or HRT. Chronic, lifelong conditions with strong retention when managed well. Higher CAC, but the ratio holds because LTV is exceptional.

If you want fastest path to refill cash flow: ED (ongoing protocol, not as-needed). Short intake, clear treatment protocol, high repeat rate once onboarded.

What to avoid as an anchor: Building your entire business around a single compound in a category facing regulatory uncertainty is how operators get stranded. The compounded GLP-1 window is a cautionary example — operators who diversified into TRT, HRT, hair, and LDN alongside it are fine. Those who bet the whole business on one compound and one pharmacy are repricing that risk right now.

Diversify your formulary breadth early, and build your fulfillment rails to support multi-pharmacy routing so you can adapt when a pharmacy's formulary shifts.

---

The Ownership Calculation: Three Things That Actually Move Your Blended LTV:CAC

1. Own the patient record from day one. The patient's intake data, prescription history, lab results, and preferences should live in a system you control — not inside a platform's database that you can query but not export. If you cannot run a cohort analysis on your own patients without asking the platform for a report, you do not own the relationship.

2. Own the order system of record. Every order that flows through your fulfillment rail should be logged in your system first, then pushed to the pharmacy. Not the reverse. This matters for audit, for portability, and for the cross-sell queries you will want to run at scale.

3. Own the refill trigger. Your CRM — not your pharmacy's automation — should fire the refill reminder. When you own the trigger, you control the timing, the message, the offer, and the attribution. When the pharmacy fires the reminder, you get the refill but you cede the relationship.

[See how neolife positions your Shopify store as the system of record →]

---

Key Takeaways

• CAC ranges widely by category: $50–$110 for skin/hair, $150–$350 for TRT/HRT (estimated from public sources). Know your category before you model.
• Target LTV:CAC of 4–6:1. Below 3:1 is not a scalable acquisition model. Above 6:1 suggests you are under-investing in growth.
• Platform revenue share of 20–25% effectively cuts your LTV:CAC ratio by 15–25%. This compounds into meaningful equity destruction at scale.
• The 90-day refill window is where your retention program earns its keep. Operators who actively manage that window outperform by 30–50% on 12-month LTV.
• Multi-protocol cross-sell is the highest-leverage LTV move available. It requires owning the patient record and the order rail.
• Diversify your formulary and your pharmacy routing early. Single-compound dependency is a regulatory liability. TRT, HRT, hair, ED, tretinoin, LDN, and peptides are all proven, durable categories.
• Provider approval is non-negotiable and is also a retention advantage. Every refill reviewed by a licensed provider is a brand trust signal. Lead with it.

---

Frequently Asked Questions

Q: What is a good CAC for a telehealth clinic? A: It depends on category. Skin and hair protocols typically run $50–$130 CAC. TRT and HRT run $120–$350. The benchmark that actually matters is your LTV:CAC ratio — target 4–6:1 for a sustainable acquisition model. (Estimated from public sources.)

Q: How long does it take for a telehealth patient to become profitable? A: Most DTC Rx brands reach break-even on CAC between months two and four, assuming a monthly subscription model and the first refill conversion rate stays above 55–60%. Chronic-condition categories (TRT, HRT, LDN) typically achieve this faster due to higher AOV and retention.

Q: Does platform revenue share really matter at small scale? A: At 100 patients, a 20% revenue share is painful but survivable. At 1,000 patients and a $1,100 12-month LTV, it is $220,000 in annual margin that belongs to the platform rather than your P&L. It matters at every scale — the logic just becomes harder to ignore as you grow.

Q: What telehealth category has the best LTV? A: TRT, HRT, and LDN consistently produce the highest 12-month LTV in operator data — driven by chronic-condition retention, strong patient motivation, and relatively high AOV. Hair and ED produce good LTV at lower AOV, especially when managed on a subscription cadence.

Q: How does owning the patient record affect unit economics? A: It enables cross-sell without additional CAC, gives you the data to optimize retention by cohort, lets you move pharmacy routing without losing patient history, and keeps refill reminders — and the brand equity they build — inside your own stack rather than your vendor's.

---

neolife connects your Shopify store directly to your compounding pharmacy — orders dispatch in under 60 seconds after provider approval, and your clinic stays the system of record. If you are modeling unit economics for a DTC Rx launch or trying to understand why your LTV:CAC is compressing, talk to us. We have seen this movie before.

Nothing in this post constitutes legal or medical advice. Verify compliance specifics with your counsel and your pharmacy. CAC and LTV figures are directional estimates from public sources; your results will vary by category, channel, and operational execution.